USP 1217 Tablet Breaking Force: The Complete Pharmaceutical Lab GuideUSP 1217 Tablet Breaking Force Test

The USP 1217 tablet breaking force test is the United States Pharmacopeia's informational chapter describing how to measure the crushing force required to fracture a tablet under diametral compression — a key physical quality attribute for every commercial tablet dosage form. Formally titled General Chapter <1217> Tablet Breaking Force, it sits in the USP's informational tier (numbered above 1000) yet is cross-referenced by product monographs and treated as the de facto mandatory method for US pharmaceutical QC labs.

This guide covers every sub-section of USP <1217>: the equipment specifications the chapter implies, the test procedure step by step, the acceptance criteria typically written into tablet product specifications, and the validation documentation a lab must keep. Any QC manager, R&D formulator, or regulatory-affairs specialist preparing a tablet dossier for the US market needs to be fluent in USP <1217>.

What Is USP Chapter 1217 and Who Must Comply?

USP <1217> defines tablet breaking force as the force required to cause a tablet to fracture under a slowly applied diametral compression between two opposing flat, parallel jaws. The quantity is reported in newtons (N). Although the chapter is informational, it is invoked through product monographs and compendial compliance language in CMC sections of INDs, NDAs, ANDAs, and DMFs. The US FDA's 21 CFR 211.110(a)(5) requires in-process controls for tablets including hardness, and the industry convention is that this means breaking force per USP <1217>.

Under ICH Q4B Annex 5, USP <1217> is partially harmonized with EP 2.9.8 and JP 6.09. The key differences are sample size and reporting format. A lab running a single n = 10 test set, correctly documented, can satisfy all three pharmacopeias.

• US-market tablet manufacturers — branded, generic, OTC; every batch released to the US market should carry a USP <1217> breaking-force result
• Contract manufacturers (CMOs/CDMOs) producing for US MA holders
• Contract research organizations (CROs) running stability studies or bio-equivalence batches for US submissions
• Generic-drug sponsors — ANDAs routinely reference USP <1217> in pharmaceutical development and in-process control sections
• Compounding pharmacies under 503B outsourcing

Equipment Requirements: Force Range, Accuracy & Calibration per USP 1217

USP <1217> states performance requirements in functional terms. The chapter calls for an instrument capable of applying a gradually increasing force diametrally to the tablet via two opposing flat, polished, parallel jaws. Translating those functional requirements into purchase specifications for a pharmaceutical texture analyzer produces the following guidance.

Step-by-Step USP 1217 Test Procedure

The procedure below is a compliance-ready SOP skeleton. Adapt it to your product monograph and lab quality management system. All steps generate audit-trail entries in a 21 CFR Part 11-compliant system.

• Verify the instrument status — calibration current, no unresolved OOS events in audit trail, environmental conditions within spec (21 ± 2 °C, 45 ± 15% RH)
• Log in under your own user ID — do not share accounts; the Part 11 audit trail requires attributable operator identity
• Install the tablet-hardness jaws — flat, parallel, polished, hardened steel; verify parallelism within manufacturer specification
• Select the appropriate load cell — 500 N for standard tablets; confirm by software interlock that the load cell matches the method
• Load the SOP-locked method — test speed 1.0 or 2.0 mm/s; trigger force 0.05 N; break detection 40% force drop from peak; data acquisition 500 Hz
• Prepare the tablet sample — at least n = 6 per product monograph; equilibrate to lab conditions; visually inspect and reject chipped or laminated specimens
• Load each tablet — orient oblong/caplet tablets along minor axis; round biconvex with flat band parallel to jaw face; scored tablets with score perpendicular to force
• Execute the test — upper jaw descends at configured rate; software captures peak force and full force-vs-distance curve
• Inspect the fracture — confirm clean diametral break; flag laminar splits, multiple peaks, or crumble; investigate if systematic
• Operator review and e-signature — review curves, confirm data quality, apply Part 11 e-signature with meaning 'Tested by'
• QC supervisor review — independent second-person review of results and audit trail; apply e-signature 'Reviewed and approved'
• Compare to specification — mean within limits, minimum individual value above floor, RSD within precision target
• Disposition — pass or fail logged; if fail, invoke OOS investigation per SOP and FDA 2006 OOS Guidance
• Archive — raw data, processed results, audit trail, and signatures retained per retention schedule (typically ≥ 5 years after product expiry)

Acceptance Criteria: Minimum Hardness, n-Value & Outlier Rules

USP <1217> itself does not prescribe numerical acceptance criteria — the chapter is a method, not a specification. Acceptance criteria are set in the product monograph, manufacturing specification, or stability protocol. The following practical guidance applies to most QC tablet work.

Any individual value falling outside the specification triggers an OOS investigation per 21 CFR 211.192 and the FDA's 2006 OOS Guidance. Arbitrary deletion of data is not permitted — every excluded data point requires a documented, science-based justification retained in the audit trail.

Common Sources of Variability and How to Control Them

USP <1217> results are sensitive to operator technique, instrument configuration, and sample condition. Controlling these variables is the primary lever for reducing between-operator or between-lab variability.

• Tablet orientation — a 10° rotation on the jaw can change breaking force by 20–30%; the SOP must specify orientation with a photograph or diagram
• Jaw wear and cleanliness — film-coating debris on jaws alters contact geometry; clean with lint-free wipe between batches; document jaw serial number
• Environmental conditioning — tablets are hygroscopic; moisture pickup at elevated humidity reduces breaking force by 10–30%; maintain 45 ± 15% RH
• Loading rate — tablets are viscoelastic; fix test speed at 1.0 or 2.0 mm/s and use the same rate for all stability and release testing
• Load cell range mismatch — a 500 N cell measuring a 20 N tablet loses effective resolution; use 50 N or 100 N cells for orodispersible tablets
• Operator-to-operator variability — run annual inter-operator comparison (n = 10 on same reference batch); target ≤ 5% RSD operator-to-operator

Calibration Schedule and Validation Maintenance

For a USP <1217> tablet hardness method on a modern pharmaceutical texture analyzer, the maintenance cadence balances GMP compliance requirements with practical lab operations.

Cost Considerations for USP 1217 Method Implementation

For a lab setting up a new USP <1217> capability or migrating from a legacy dedicated hardness tester to a multi-purpose texture analyzer, the typical 5-year cost comparison between Enterprise-brand instruments and the KHT TA-30 reflects the impact of optional vs. included compliance features.